Is There a Correlation Between Peptide Receptor Radionuclide Therapy-Associated Hematological Toxicity and Spleen Dose?
Authors:
- 24 August 2012
- book chapter
- Published by Springer Nature
- Vol. 194, 561-566
Abstract
Aim: The spleen receives a high mean absorbed radiation dose during peptide receptor radionuclide therapy (PRRNT). The aim of this study is to correlate the radiation dose to spleen with the effect on blood cell count after PRRNT. Methods: Fifty-three neuroendocrine tumor (NET) patients were treated with 3.8–8.5 GBq 177Lu-DOTATATE or 177Lu-DOTATOC. Dosimetry was performed according to MIRD scheme. Eleven NET patients who had undergone splenectomy before PRRNT and who received 4.7–7.6 GBq 177Lu-DOTATATE or 177Lu-DOTATOC were selected as controls. RBC, WBC (total and differential), and platelet counts before and after each cycle of PRRNT were documented. Results: The median dose to the spleen in the study group was 6.34 Gy (2.32–20.06 Gy). There was no significant difference in the posttherapy changes in the blood cell counts (RBC, WBC, or platelets) between the study group and the control group. Mild hematological toxicity was found in 7 of the 53 (13.2%) patients in the study group and in 1 out of the 11 patients (9.1%) in the control group. However, there was no correlation between the incidence or grade of hematological toxicity and the dose to the spleen. Conclusion: This study demonstrates for the first time that hematological toxicity after PRRNT is not related to the radiation dose to the spleen.Keywords
This publication has 7 references indexed in Scilit:
- Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory SitesScience, 2009
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and SurvivalJournal of Clinical Oncology, 2008
- Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with 177 Lu DOTA-TATE and 177 Lu DOTA-NOCCancer Biotherapy and Radiopharmaceuticals, 2007
- Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumoursActa Oncologica, 2007
- Peptide Receptor Radionuclide TherapyAnnals of the New York Academy of Sciences, 2004
- Clinical indications and biological mechanisms of splenic irradiation in chronic leukaemias and myeloproliferative disordersRadiotherapy and Oncology, 2001
- Distribution of somatostatin receptors in normal and tumor tissueMetabolism, 1990